Delfi Diagnostics’ AI-based blood test detects 80% of early-stage lung cancer cases, study finds
These days, cancer-spotting liquid biopsy offerings are a dime a dozen, with everyone from Grail to Guardant throwing their hats in the ring and cancer-screening blood test developers making up three of the top five highest-funded medtech companies in 2020.
But while Delfi Diagnostics’ goal of creating a more accurate and affordable method to detect early-stage cancers reflects the aims of its many competitors in the space, it’s taking a different approach to get there.
That approach—which looks for millions of possible abnormalities in the breakages of a patient’s cell-free DNA molecules, rather than looking for cancer in genetic mutations or methylation groups—seems to have paid off.
According to a study of just under 800 patients that was published Friday in the journal Nature Communications, Delfi’s test was able to spot about 90% of lung cancer cases, including 80% of stage 1 cases. The results were validated by low-dose CT (LDCT) scans, which are recommended for high-risk patients ages 50 and up to screen for lung cancer but are rarely performed.
Click here to read more via Fierce Biotech.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
